The success of the rapid development of mRNA vaccines against COVID-19 will enable the mRNA companies to bring their other products to market as well, many of which had been simmering in clinical trials for years before the pandemic. The most promising targets for new mRNA therapies include several types of cancer, as well as liver disease and multiple sclerosis. Michael Gross reports.
The renaissance of RNA therapies